Basic Stats
| CIK | 1168197 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Liposcience Inc
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| February 17, 2015 |
LPDX / Liposcience Inc / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| February 17, 2015 |
LPDX / Liposcience Inc / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 12, 2015 |
LPDX / Liposcience Inc / Sightline Healthcare Management Iii, L.p. - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* LipoScience, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 53630M108 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedu |
|
| November 24, 2014 |
LPDX / Liposcience Inc S-8 POS - - S-8 POS S-8 POS As filed with the Securities and Exchange Commission on November 24, 2014 Registration No. |
|
| November 24, 2014 |
LPDX / Liposcience Inc POS AM - - POS AM POS AM As filed with the Securities and Exchange Commission on November 24, 2014 Registration No. |
|
| November 24, 2014 |
LPDX / Liposcience Inc / Laboratory Corp Of America Holdings - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO §240.13d-1(a). UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* LipoScience, Inc. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 53630M10 |
|
| November 24, 2014 |
LPDX / Liposcience Inc S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on November 24, 2014 Registration No. |
|
| November 21, 2014 |
LABCORP COMPLETES ACQUISITION OF LIPOSCIENCE LABCORP COMPLETES ACQUISITION OF LIPOSCIENCE BURLINGTON, N.C. November 21, 2014 - Laboratory Corporation of America® Holdings (NYSE: LH) today announced the completion of its acquisition of LIPOSCIENCE, Inc. (NASDAQ: LPDX), effective November 20, 2014. At a special meeting held on November 20, 2014, LIPOSCIENCE’s stockholders approved the acquisition and the transaction closed promptly thereafter. |
|
| November 21, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2014 LIPOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-35792 56-1879288 (Commission Fil |
|
| November 12, 2014 |
LipoScience Announces 2014 Third Quarter Financial Results Exhibit 99.1 LipoScience Announces 2014 Third Quarter Financial Results RALEIGH, N.C., November 12, 2014 (GLOBE NEWSWIRE) - LipoScience, Inc. (NASDAQ: LPDX) today announced its financial results for the third quarter ended September 30, 2014. Third Quarter 2014 Highlights • Quarterly revenue decreased 5% sequentially and 33% year-over-year to $8.6 million • Net loss was $4.3 million and Basic and |
|
| November 12, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2014 LIPOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-35792 56-1879288 (Commission Fil |
|
| November 12, 2014 |
LPDX / Liposcience Inc DEFA14A - - DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (RULE 14a-101) Filed by the Registrant ý Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement ý Definitive Additional Materials ¨ Soliciting Material Pursuant to § 240. |
|
| November 12, 2014 |
LPDX / Liposcience Inc 10-Q - Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2014 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-35792 LIPOSCIENCE, INC. (Exact name of |
|
| November 10, 2014 |
LPDX / Liposcience Inc DEFA14A - - DEFINITIVE ADDITIONAL MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (RULE 14a-101) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definit |
|
| October 27, 2014 |
LPDX / Liposcience Inc DEFA14A - - DEFINITIVE ADDITIONAL MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (RULE 14a-101) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definit |
|
| October 20, 2014 |
LPDX / Liposcience Inc DEFM14A - - DEFM14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (RULE 14a-101) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definit |
|
| October 15, 2014 |
LPDX / Liposcience Inc DEFA14A - - DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (RULE 14a-101) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definit |
|
| October 15, 2014 |
LPDX / Liposcience Inc DEFA14A - - DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (RULE 14a-101) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definit |
|
| October 8, 2014 |
LPDX / Liposcience Inc PREM14A - - PRELIMINARY PROXY STATEMENT - MERGER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (RULE 14a-101) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))870 ¨ Defi |
|
| October 3, 2014 |
LPDX / Liposcience Inc / Laboratory Corp Of America Holdings - SC 13D Activist Investment SC 13D SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO §240.13d-1(a). UNDER THE SECURITIES EXCHANGE ACT OF 1934 LipoScience, Inc. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 53630M108 (CUSIP Number) F. S |
|
| September 26, 2014 |
LPDX / Liposcience Inc DEFA14A - - DEFA14A DEFA14A 1 v390129defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (RULE 14a-101) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as per |
|
| September 25, 2014 |
Exhibit 99.1 VOTING AGREEMENT This VOTING AGREEMENT (this “Agreement”), dated as of September 24, 2014, is made by and between Laboratory Corporation of America Holdings, a Delaware corporation (“Parent”), and the undersigned holder (the “Stockholder”) of shares of common stock, par value $0.001 per share (the Common Stock”), of LipoScience, Inc., a Delaware corporation (the “Company”). WHEREAS, P |
|
| September 25, 2014 |
LPDX / Liposcience Inc DEFA14A - - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 24, 2014 LIPOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-35792 56-1879288 (Commission Fi |
|
| September 25, 2014 |
Exhibit 99.2 FOR IMMEDIATE RELEASE LABCORP ANNOUNCES AGREEMENT TO ACQUIRE LIPOSCIENCE Acquisition Price of $5.25 Per Share in All Cash Transaction NMR LipoProfile test expands LabCorp’s offering of personalized diagnostic tests BURLINGTON, NC, September 25, 2014 — Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) and LipoScience, Inc. (NASDAQ: LPDX), a provider of specialized cardi |
|
| September 25, 2014 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER Dated as of September 24, 2014 among Laboratory Corporation of America Holdings Bear Acquisition Corp. and LipoScience, Inc. The Merger Agreement contains representations and warranties by the parties thereto. A party’s representations and warranties were made solely for the benefit of the other party or parties and (i) were not intended to be treated as ca |
|
| September 25, 2014 |
LPDX / Liposcience Inc DEFA14A - - FORM DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (RULE 14a-101) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definit |
|
| September 25, 2014 |
Exhibit 99.2 FOR IMMEDIATE RELEASE LABCORP ANNOUNCES AGREEMENT TO ACQUIRE LIPOSCIENCE Acquisition Price of $5.25 Per Share in All Cash Transaction NMR LipoProfile test expands LabCorp’s offering of personalized diagnostic tests BURLINGTON, NC, September 25, 2014 — Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) and LipoScience, Inc. (NASDAQ: LPDX), a provider of specialized cardi |
|
| September 25, 2014 |
LPDX / Liposcience Inc DEFA14A - - FORM DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (RULE 14a-101) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definit |
|
| September 25, 2014 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER Dated as of September 24, 2014 among Laboratory Corporation of America Holdings Bear Acquisition Corp. and LipoScience, Inc. The Merger Agreement contains representations and warranties by the parties thereto. A party’s representations and warranties were made solely for the benefit of the other party or parties and (i) were not intended to be treated as ca |
|
| September 25, 2014 |
Exhibit 99.1 VOTING AGREEMENT This VOTING AGREEMENT (this “Agreement”), dated as of September 24, 2014, is made by and between Laboratory Corporation of America Holdings, a Delaware corporation (“Parent”), and the undersigned holder (the “Stockholder”) of shares of common stock, par value $0.001 per share (the Common Stock”), of LipoScience, Inc., a Delaware corporation (the “Company”). WHEREAS, P |
|
| September 25, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 24, 2014 LIPOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-35792 56-1879288 (Commission Fi |
|
| September 25, 2014 |
LPDX / Liposcience Inc DEFA14A - - DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (RULE 14a-101) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definit |
|
| August 12, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2014 LIPOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-35792 56-1879288 (Commission File |
|
| August 12, 2014 |
Exhibit 99.1 LipoScience Announces 2014 Second Quarter Financial Results Achieves Second Quarter Revenue Guidance Healthcore Study Provides Compelling Data on Reduction in Cardiovascular Disease Risk and Events RALEIGH, N.C., August 12, 2014 (GLOBE NEWSWIRE) - LipoScience, Inc. (NASDAQ: LPDX) today announced its financial results for the second quarter ended June 30, 2014. Second Quarter 2014 High |
|
| June 12, 2014 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2014 LIPOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-35792 56-1879288 (Commission File No |
|
| May 12, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2014 LIPOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-35792 56-1879288 (Commission File No. |
|
| May 12, 2014 |
LIPOSCIENCE ANNOUNCES 2014 FIRST QUARTER FINANCIAL RESULTS Exhibit 99.1 Media Contact: Investor Contact: Tori Hall Bob Yedid LipoScience, Inc. ICR, Inc. (919) 256-1046 (646) 277-1250 [email protected] [email protected] LIPOSCIENCE ANNOUNCES 2014 FIRST QUARTER FINANCIAL RESULTS RALEIGH, N.C., May 12, 2014 -LipoScience, Inc. (NASDAQ: LPDX), a diagnostic company pioneering a new field of personalized nuclear magnetic resonance (NMR) diagnostics to |
|
| May 5, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2014 LIPOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-35792 56-1879288 (Commission File No.) |
|
| May 5, 2014 |
Exhibit 99.1 Media Relations: Investor Relations: Tori Hall Bob Yedid LipoScience, Inc. ICR, Inc. (919) 256-1046 (646) 277-1250 [email protected] [email protected] LIPOSCIENCE ANNOUNCES CASH MANAGEMENT ACTIONS RALEIGH, N.C. - May 5, 2014 - In a proactive effort to manage its cash, LipoScience, Inc. (NASDAQ: LPDX) today announced a reduction in workforce. This announcement represents the |
|
| April 29, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 28, 2014 |
S-8 1 lpdxs820140328.htm S-8 As filed with the Securities and Exchange Commission on March 28, 2014 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 LIPOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 56-1879288 (State or other jurisdiction of incorporation or |
|
| March 20, 2014 |
LPDX / Liposcience Inc / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| March 14, 2014 |
LipoScience, Inc. Senior Leadership Team Annual Incentive Compensation Plan Terms Exhibit 10.1 LipoScience, Inc. Senior Leadership Team Annual Incentive Compensation Plan Terms 1. Plan Objective: The LipoScience, Inc. Senior Leadership Team Annual Incentive Plan (referred to as the “Plan”) is designed to focus key employee behavior on achievement of Company objectives and strategy as well as align the interests of management to those of stockholders. 2. Administration: The Plan |
|
| March 14, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2014 LIPOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-35792 56-1879288 (Commission File N |
|
| March 10, 2014 |
LIPOSCIENCE ANNOUNCES 2013 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS Exhibit 99.1 Media Contact: Investor Contact: Tori Hall Bob Yedid LipoScience, Inc. ICR, Inc. (919) 256-1046 (646) 277-1250 [email protected] [email protected] LIPOSCIENCE ANNOUNCES 2013 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS RALEIGH, N.C., March 10, 2014 -LipoScience, Inc. (NASDAQ: LPDX), a diagnostic company pioneering a new field of personalized nuclear magnetic resonance (NM |
|
| March 10, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2014 LIPOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-35792 56-1879288 (Commission File N |
|
| February 20, 2014 |
LPDX / Liposcience Inc / Sightline Healthcare Management Iii, L.p. - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* LipoScience, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 53630M108 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedu |
|
| February 14, 2014 |
LPDX / Liposcience Inc / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| February 13, 2014 |
LPDX / Liposcience Inc / THREE ARCH CAPITAL LP - SC 13G Passive Investment SC 13G 1 v368326sc13g.htm SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. )* LipoScience, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 53630M108 (CUSIP Number) December 31, 2013 (Date of Event Wh |
|
| January 22, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2014 LIPOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-35792 56-1879288 (Commission File |
|
| January 22, 2014 |
Exhibit 99.1 Media Relations: Investor Relations: Tori Hall Bob Yedid LipoScience, Inc. ICR, Inc. (919) 256-1046 (646) 277-1250 [email protected] [email protected] LipoScience Announces Appointment of Howard Doran as President and Chief Executive Officer Senior Executive from Cytyc Corporation, Hologic, Inc. and Constitution Medical Brings Deep IVD Leadership Experience to LipoScience R |
|
| January 22, 2014 |
EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of January 17, 2014, (the “Effective Date”), by and between HOWARD B. DORAN, JR. (“Executive”) and LIPOSCIENCE, INC. (the “Company”). This Agreement supersedes and replaces in its entirety all prior offer letters, employment agreements and severance benefits rights agreements between the Com |
|
| November 5, 2013 |
Media Contact: Investor Contact: Tori Hall Bob Yedid LipoScience, Inc. ICR, Inc. (919) 256-1046 (646) 277-1250 [email protected] [email protected] LIPOSCIENCE REPORTS THIRD QUARTER 2013 FINANCIAL RESULTS Third Quarter 2013 NMR LipoProfile® Test Volumes Up 3.8% from 2012 Period Third Quarter 2013 Revenue at $12.7 Million Down 6.1% from 2012 Period Company Narrows Revenue Guidance for Cal |
|
| November 5, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2013 LIPOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-35792 56-1879288 (Commission File |
|
| October 18, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2013 LIPOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-35792 56-1879288 (Commission File |
|
| September 19, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2013 LIPOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-35792 56-1879288 (Commission Fi |
|
| August 28, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2013 LIPOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-35792 56-1879288 (Commission File |
|
| August 26, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2013 LIPOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-35792 56-1879288 (Commission File |
|
| August 9, 2013 |
LIPOSCIENCE ANNOUNCES TWO NEW MEMBERS OF BOARD OF DIRECTORS LIPOSCIENCE ANNOUNCES TWO NEW MEMBERS OF BOARD OF DIRECTORS RALEIGH, N.C. - August 8, 2013 - LipoScience, Inc. (NASDAQ: LPDX) today announced that two new members have recently joined the Board of Directors, Jeffrey T. Barber and James R. (“Bob”) Hurley. Mr. Barber was elected as a director at the Annual Meeting on June 12, 2013, and Mr. Hurley was appointed a director on August 5, 2013. “We are e |
|
| August 9, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2013 LIPOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-35792 56-1879288 (Commission File N |
|
| August 6, 2013 |
August 2, 2013 LipoScience Appoints Robert Greczyn Interim President and Chief Executive Officer Company Reports Preliminary Revenues for Second Quarter in Line With Previous Guidance Company Revises Revenue Guidance for Calendar Year 2013 to Between $52 and $54 Million RALEIGH, N. |
|
| August 6, 2013 |
August 6, 2013 LIPOSCIENCE REPORTS SECOND QUARTER 2013 FINANCIAL RESULTS Second Quarter 2013 NMR LipoProfile® Test Volumes Up 7. |
|
| August 6, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2013 LIPOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-35792 56-1879288 (Commission File N |
|
| June 12, 2013 |
Submission of Matters to a Vote of Security Holders - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8‑K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2013 LipoScience, Inc. |
|
| May 17, 2013 |
LPDX / Liposcience Inc / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| May 9, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2013 LIPOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-35792 56-1879288 (Commission File No.) |
|
| May 9, 2013 |
FOR RELEASE – May 9, 2013 LIPOSCIENCE REPORTS FIRST QUARTER 2013 FINANCIAL RESULTS First Quarter 2013 NMR LipoProfile® Test Volumes Up 8. |
|
| May 3, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2013 LIPOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-35792 56-1879288 (Commission File N |
|
| April 29, 2013 |
Schedule 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 27, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2013 LIPOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-35792 56-1879288 (Commission File N |
|
| March 27, 2013 |
FOR RELEASE – March 27, 2013 LIPOSCIENCE REPORTS FOURTH QUARTER AND FULL YEAR 2012 FINANCIAL RESULTS NMR LipoProfile® Test Volumes Rise 29. |
|
| March 18, 2013 |
Regulation FD Disclosure - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2013 LIPOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 001-35792 56-1879288 (State or other jurisdiction of incorporation) (Commissi |
|
| February 8, 2013 |
Exhibit 4.19 Exhibit 4.19 LIPOSCIENCE, INC. 2012 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: MAY 24, 2012 APPROVED BY THE STOCKHOLDERS: MAY 30, 2012 1. GENERAL; PURPOSE. (a) The Plan provides a means by which Eligible Employees of the Company and certain Designated Companies may be given an opportunity to purchase shares of Common Stock. The Plan permits the Company to grant a |
|
| February 8, 2013 |
Exhibit 4.16 Exhibit 4.16 LIPOSCIENCE, INC. 2012 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: MAY 24, 2012 APPROVED BY THE STOCKHOLDERS: MAY 30, 2012 TERMINATION DATE: MAY 24, 2022 1. GENERAL. (a) Eligible Award Recipients. Employees, Directors and Consultants are eligible to receive awards. (b) Available Awards. The Plan provides for the grant of the following Awards: (i) Incentive St |
|
| February 8, 2013 |
S-8 As filed with the Securities and Exchange Commission on February 8, 2013 Registration No. |
|
| February 4, 2013 |
LPDX / Liposcience Inc / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| January 30, 2013 |
THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION LIPOSCIENCE, INC. Exhibit 3.1 THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF LIPOSCIENCE, INC. LIPOSCIENCE, INC., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), does hereby certify as follows: FIRST: The name of the Corporation is LipoScience, Inc. SECOND: The Corporation’s original Certificate of Incorporation (the “Original Certificate”) was filed wit |
|
| January 30, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2013 LIPOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-35792 56-1879288 (Commis |
|
| January 30, 2013 |
Exhibit 3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF LIPOSCIENCE, INC. (A DELAWARE CORPORATION) TABLE OF CONTENTS Page ARTICLE I OFFICES 2 Section 1. Registered Office 2 Section 2. Other Offices 2 ARTICLE II CORPORATE SEAL 2 Section 3. Corporate Seal 2 ARTICLE III STOCKHOLDERS’ MEETINGS 2 Section 4. Place Of Meetings 2 Section 5. Annual Meetings 2 Section 6. Special Meetings 6 Section 7. Notice |
|
| January 25, 2013 |
424(b)(4) Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-175102 PROSPECTUS 5,000,000 Shares Common stock This is the initial public offering of the common stock of LipoScience, Inc. We are offering 5,000,000 shares of our common stock. No public market currently exists for our common stock. Our common stock has been approved for listing on The NASDAQ Global Market under th |
|
| January 24, 2013 |
Form S-1, Amendment No. 8 Table of Contents As filed with the Securities and Exchange Commission on January 24, 2013 Registration No. 333-175102 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 8 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 LIPOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 8071 56-1879288 ( |
|
| January 24, 2013 |
Form 8-A12B SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(B) OR (G) OF THE SECURITIES EXCHANGE ACT OF 1934 LipoScience, Inc. |
|
| January 24, 2013 |
FOURTH AMENDMENT OF THE LIPOSCIENCE, INC. 2007 STOCK INCENTIVE PLAN Exhibit 10.16.1 Exhibit 10.16.1 FOURTH AMENDMENT OF THE LIPOSCIENCE, INC. 2007 STOCK INCENTIVE PLAN THIS FOURTH AMENDMENT to the LipoScience, Inc. (the “Company”) Stock Incentive Plan (the “Plan”) is effective as of August 27, 2012. WHEREAS, the Board of Directors (the “Board”) of the Company has adopted and the stockholders of the Company have approved the Plan; and WHEREAS, the Board has approve |
|
| January 24, 2013 |
Exhibit 10.37 Exhibit 10.37 *** Text Omitted and Filed Separately Confidential Treatment Requested Under 17 CFR §§ 200.80(b)(4) and 230.406 2012 Corporate Goals for Strategic Leadership Team Approved by the Compensation Committee on February 7, 2012 Revenue Growth versus Prior Year (60%) Total Revenue Growth Vs. Prior Year Funding* ³ [***]% growth 200 % ³ [***]% growth 175 % ³ [***]% growth 150 % |
|
| January 24, 2013 |
Correspondence Brent B. Siler (703) 456-8058 [email protected] VIA EDGAR January 24, 2013 U. S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 3561 Washington, D.C. 20549 Attn: Mr. John Reynolds Mr. Jay Williamson Mr. Jim Lopez Mr. Steve Lo Mr. John Archfield RE: LipoScience, Inc. Amendment to Registration Statement on Form S-1 Filed January 10, 201 |
|
| January 24, 2013 |
Amendment #9 Table of Contents As filed with the Securities and Exchange Commission on January 24, 2013 Registration No. |
|
| January 24, 2013 |
Exhibit 10.9.2 EXHIBIT 10.9.2 Supply Agreement THIS SUPPLY AGREEMENT (the “Agreement”) dated as of July 16, 2012 (the “Effective Date”), is made by and between: LIPOSCIENCE, INC., a corporation organized and existing under the laws of the State of Delaware having its offices at 2500 Sumner Boulevard, Raleigh, North Carolina 27616 (“LipoScience”) as customer. And AGILENT TECHNOLOGIES, INC., a corpo |
|
| January 24, 2013 |
Issuer Free Writing Prospectus FWP 1 d339769dfwp.htm FREE WRITING PROPSECTUS Issuer Free Writing Prospectus Relating to Preliminary Prospectus dated January 10, 2013 Filed Pursuant to Rule 433 Registration Statement No. 333–175102 January 24, 2013 This free writing prospectus relates to the initial public offering of common stock by LipoScience, Inc. (the “Offering”) and should be read together with the preliminary prospectus, |
|
| January 23, 2013 |
CORRESP 1 filename1.htm 2500 Sumner Boulevard Raleigh, North Carolina 27616 VIA EDGAR January 22, 2013 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 3561 Washington, D.C. 20549 Attn: Mr. John Reynolds Mr. Jay Williamson Mr. Jim Lopez Re: LipoScience, Inc. Registration Statement on Form S-1 File No. 333-175102 Acceleration Request Requested Dat |
|
| January 23, 2013 |
Correspondence Brent B. Siler (703) 456-8058 [email protected] Via FAX January 23, 2013 U. S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 3561 Washington, D.C. 20549 Attn: Mr. John Reynolds Mr. Jay Williamson Mr. Jim Lopez Mr. Steve Lo Mr. John Archfield RE: LipoScience, Inc. Amendment No. 8 to Registration Statement on Form S-1 Registration No. |
|
| January 22, 2013 |
Correspondence Brent B. Siler (703) 456-8058 [email protected] VIA EDGAR AND HAND DELIVERY January 22, 2013 U. S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 3561 Washington, D.C. 20549 Attn: Mr. John Reynolds Mr. Jay Williamson Mr. Jim Lopez Mr. Steve Lo Mr. John Archfield RE: LipoScience, Inc. Amendment No. 8 to Registration Statement on Form S |
|
| January 10, 2013 |
Amended and Restated Employment Agreement Exhibit 10.32 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”) is entered into on , 2013, (the “Effective Date”), by and between ROBERT M. HONIGBERG, M.D. (“Employee”) and LIPOSCIENCE, INC. (the “Company”). This Agreement supersedes and replaces in its entirety all prior offer letters, employment agreements and severance benefits rights ag |
|
| January 10, 2013 |
THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION LIPOSCIENCE, INC. THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Exhibit 3.3 THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF LIPOSCIENCE, INC. LIPOSCIENCE, INC., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), does hereby certify as follows: FIRST: The name of the Corporation is LipoScience, Inc. SECOND: The Corporation’s original Certificate of |
|
| January 10, 2013 |
Exhibit 10.3.1 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBS |
|
| January 10, 2013 |
Table of Contents As filed with the Securities and Exchange Commission on January 10, 2013 Registration No. |
|
| January 10, 2013 |
CERTIFICATE OF AMENDMENT SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION LIPOSCIENCE, INC. SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Exhibit 3.1.1 CERTIFICATE OF AMENDMENT TO SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF LIPOSCIENCE, INC. LIPOSCIENCE, INC., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify as of this 8th day of January, 2013: FIRST: The na |
|
| January 10, 2013 |
WARRANT TO PURCHASE SERIES E PREFERRED STOCK Exhibit 10.2 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS, AND MAY NOT BE SOLD, PLEDGED OR OTHERWISE TRANSFERRED EXCEPT IN ACCORDANCE WITH APPLICABLE LAW. WARRANT TO PURCHASE STOCK Corporation: LIPOSCIENCE, INC. Number of Shares: 27,586 (Subj |
|
| January 10, 2013 |
5,000,000 Shares LIPOSCIENCE, INC. Common Stock UNDERWRITING AGREEMENT FORM OF UNDERWRITING AGREEMENT Exhibit 1.1 5,000,000 Shares LIPOSCIENCE, INC. Common Stock UNDERWRITING AGREEMENT [•], 2013 BARCLAYS CAPITAL INC. UBS SECURITIES LLC PIPER JAFFRAY & CO. As Representatives of the several Underwriters named in Schedule I attached hereto Barclays Capital Inc. 745 Seventh Avenue New York, New York 10019 UBS Securities LLC 299 Park Avenue New York, New York 10171 Piper |
|
| January 10, 2013 |
CERTIFICATE OF AMENDMENT SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION LIPOSCIENCE, INC. SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Exhibit 3.2 CERTIFICATE OF AMENDMENT TO SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF LIPOSCIENCE, INC. LIPOSCIENCE, INC., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify as of this 10th day of January, 2013: FIRST: The nam |
|
| January 10, 2013 |
Specimen Common Stock Certificate Exhibit 4.2 CUSIP XXXXXX XX X Holder ID XXXXXXXXXX Insurance Value 00.1,000,000 Number of Shares 123456 DTC 12345678901234512345678 PO BOX 43004, Providence, RI 02940-3004 Certificate Numbers Num/No Denom. Total. MR A SAMPLE 1234567890/1234567890 111 DESIGNATION (IF ANY) 1234567890/1234567890 222 ADD 1 ADD 2 1234567890/1234567890 333 1234567890/1234567890 444 ADD |
|
| January 10, 2013 |
Exhibit 10.3.2 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBS |
|
| January 10, 2013 |
LOAN AND SECURITY AGREEMENT Exhibit 10.1 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (as the same may from time to time be amended, modified, supplemented or restated, this “Agreement”) dated as of December 20, 2012 (the “Effective Date”) among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“ |
|
| January 2, 2013 |
Correspondence Brent B. Siler VIA EDGAR AND FAX (703) 456-8058 [email protected] January 2, 2013 U. S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 3561 Washington, D.C. 20549 Attn: Mr. John Reynolds Mr. Jay Williamson Mr. Jim Lopez RE: LipoScience, Inc. Amendment No. 6 to Registration Statement on Form S-1 Registration No. 333-175102 Ladies and G |
|
| December 4, 2012 |
Amendment No. 6 to Form S-1 Table of Contents As filed with the Securities and Exchange Commission on December 4, 2012 Registration No. 333-175102 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 6 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 LIPOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 8071 56-1879288 |
|
| December 4, 2012 |
CORRESP Brent B. Siler (703) 456-8058 [email protected] VIA EDGAR AND HAND DELIVERY December 4, 2012 U. S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 3561 Washington, D.C. 20549 Attn: Mr. John Reynolds Mr. Jay Williamson Mr. Jim Lopez Mr. Steve Lo Mr. John Archfield RE: LipoScience, Inc. Amendment No. 6 to Registration Statement on Form S-1 Regi |
|
| December 4, 2012 |
1 THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE DESIGNATED [***]. A COMPLETE Exhibit 10.35 Exhibit 10.35 AGREEMENT This Agreement (“Agreement”) is entered into by and between Laboratory Corporation of America Holdings, a Delaware corporation having a place of business at 531 South Spring Street, Burlington, North Carolina 27215 (“LabCorp” and such entity, along with its Business Group (as defined below), may, in LabCorp’s discretion be collectively referred to as “LabCorp” |
|
| December 4, 2012 |
CORRESP Brent B. Siler T: +1 703 456 8058 [email protected] VIA EDGAR AND OVERNIGHT DELIVERY December 4, 2012 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 3561 Washington, D.C. 20549 *FOIA Confidential Treatment Request* Confidential Treatment Requested by LipoScience, Inc. in connection with Registration Statement on Form S-1 (File No. 333-1 |
|
| October 23, 2012 |
Exhibit 10.23 Exhibit 10.23 LIPOSCIENCE, INC. 2012 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: MAY 24, 2012 APPROVED BY THE STOCKHOLDERS: MAY 30, 2012 TERMINATION DATE: MAY 24, 2022 1. GENERAL. (a) Eligible Award Recipients. Employees, Directors and Consultants are eligible to receive awards. (b) Available Awards. The Plan provides for the grant of the following Awards: (i) Incentive |
|
| October 23, 2012 |
SIXTH AMENDMENT LOAN AND SECURITY AGREEMENT Exhibit 10.1.2 Exhibit 10.1.2 SIXTH AMENDMENT TO LOAN AND SECURITY AGREEMENT This Sixth Amendment to Loan and Security Agreement is entered into as of April 30, 2012 (the “Amendment”) by and between SQUARE 1 BANK (“Bank”) and LIPOSCIENCE, INC. (“Borrower”). RECITALS Borrower and Bank are parties to that certain Loan and Security Agreement dated as of February 7, 2008, as may be amended from time t |
|
| October 23, 2012 |
AMENDED AND RESTATED EMPLOYMENT AGREEMENT Exhibit 10.31 Exhibit 10.31 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is entered into on , 2012 (the “Effective Date”), by and between LUCY G. MARTINDALE (“Employee”) and LIPOSCIENCE, INC. (the “Company”). This Agreement supersedes and replaces in its entirety all prior offer letters, employment agreements and severance benefits rig |
|
| October 23, 2012 |
Correspondence Brent B. Siler (703) 456-8058 [email protected] VIA EDGAR AND HAND DELIVERY October 23, 2012 U. S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 3561 Washington, D.C. 20549 Attn: Mr. John Reynolds Mr. Jay Williamson Mr. Jim Lopez Mr. Steve Lo Mr. John Archfield RE: LipoScience, Inc. Amendment No. 5 to Registration Statement on Form S |
|
| October 23, 2012 |
LIPOSCIENCE, INC. STOCK OPTION GRANT NOTICE (2012 EQUITY INCENTIVE PLAN) Exhibit 10.24 Exhibit 10.24 LIPOSCIENCE, INC. STOCK OPTION GRANT NOTICE (2012 EQUITY INCENTIVE PLAN) LipoScience, Inc. (the “Company”) hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. The option is subject to all of the terms and conditions as set forth in this notice, in the Option Agreement and in the 2012 Equity Incentive Pl |
|
| October 23, 2012 |
Exhibit 10.33 Exhibit 10.33 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”) is entered into on , 2012 (the “Effective Date”), by and between TIMOTHY J. FISCHER (“Employee”) and LIPOSCIENCE, INC. (the “Company”). This Agreement supersedes and replaces in its entirety all prior offer letters, employment agreements and severance benefits rights agreements between the Company and Emp |
|
| October 23, 2012 |
LIPOSCIENCE, INC. EXECUTIVE SEVERANCE BENEFIT PLAN Exhibit 10.36 Exhibit 10.36 LIPOSCIENCE, INC. EXECUTIVE SEVERANCE BENEFIT PLAN 1. INTRODUCTION. This LipoScience, Inc. Executive Severance Benefit Plan (the “Plan”) is established by LipoScience, Inc. (the “Company”) on May 24, 2012 (the “Effective Date”). The Plan provides for severance payments and benefits to certain employees of the Company, including but not limited to severance benefits in c |
|
| October 23, 2012 |
Exhibit 10.34 Exhibit 10.34 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”) is entered into on , 2012 (the “Effective Date”), by and between THOMAS S. CLEMENT (“Employee”) and LIPOSCIENCE, INC. (the “Company”). This Agreement supersedes and replaces in its entirety all prior offer letters, employment agreements and severance benefits rights agreements between the Company and Empl |
|
| October 23, 2012 |
Exhibit 10.9 EXHIBIT 10.9 Supply Agreement THIS SUPPLY AGREEMENT (the “Agreement”) dated as of July 16, 2012 (the “Effective Date”), is made by and between: LIPOSCIENCE, INC., a corporation organized and existing under the laws of the State of Delaware having its offices at 2500 Sumner Boulevard, Raleigh, North Carolina 27616 (“LipoScience”) as customer. And AGILENT TECHNOLOGIES, INC., a corporati |
|
| October 23, 2012 |
Exhibit 3.5 Exhibit 3.5 AMENDED AND RESTATED BYLAWS OF LIPOSCIENCE, INC. (A DELAWARE CORPORATION) TABLE OF CONTENTS Page ARTICLE I OFFICES 2 Section 1. Registered Office 2 Section 2. Other Offices 2 ARTICLE II CORPORATE SEAL 2 Section 3. Corporate Seal 2 ARTICLE III STOCKHOLDERS’ MEETINGS 2 Section 4. Place Of Meetings 2 Section 5. Annual Meetings 2 Section 6. Special Meetings 6 Section 7. Notice |
|
| October 23, 2012 |
Amendment No. 5 to Form S-1 Table of Contents As filed with the Securities and Exchange Commission on October 23, 2012 Registration No. 333-175102 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 5 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 LIPOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 8071 56-1879288 |
|
| October 23, 2012 |
Exhibit 10.29 Exhibit 10.29 LIPOSCIENCE, INC. 2012 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: MAY 24, 2012 APPROVED BY THE STOCKHOLDERS: MAY 30, 2012 1. GENERAL; PURPOSE. (a) The Plan provides a means by which Eligible Employees of the Company and certain Designated Companies may be given an opportunity to purchase shares of Common Stock. The Plan permits the Company to grant |
|
| October 23, 2012 |
LIPOSCIENCE, INC. RESTRICTED STOCK UNIT GRANT NOTICE 2012 EQUITY INCENTIVE PLAN Exhibit 10.25 Exhibit 10.25 LIPOSCIENCE, INC. RESTRICTED STOCK UNIT GRANT NOTICE 2012 EQUITY INCENTIVE PLAN LipoScience, Inc. (the “Company”) hereby awards to Participant the number of restricted stock units (“RSUs”) set forth below (the “Award”). The Award is subject to all of the terms and conditions as set forth in this Restricted Stock Unit Grant Notice (the “Notice”), the 2012 Equity Incentiv |
|
| October 23, 2012 |
Exhibit 10.32 Exhibit 10.32 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”) is entered into on , 2012 (the “Effective Date”), by and between PAUL C. SANDERS (“Employee”) and LIPOSCIENCE, INC. (the “Company”). This Agreement supersedes and replaces in its entirety all prior offer letters, employment agreements and severance benefits rights agreements between the Company and Employ |
|
| October 23, 2012 |
AMENDED AND RESTATED EMPLOYMENT AGREEMENT Exhibit 10.30 Exhibit 10.30 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is entered into on , 2012 (the “Effective Date”), by and between RICHARD O. BRAJER (“Employee”) and LIPOSCIENCE, INC. (the “Company”). This Agreement supersedes and replaces in its entirety all prior offer letters, employment agreements and severance benefits righ |
|
| October 23, 2012 |
LIPOSCIENCE, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Exhibit 10.26.1 Exhibit 10.26.1 LIPOSCIENCE, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY On May 24, 2012, the Board of Directors (the “Board”) of LipoScience, Inc. (the “Company”) approved the following compensation policy (the “Policy”) for non-employee directors of the Company. This Policy will not be effective until the date of the initial underwritten public offering of the Company’s common |
|
| October 23, 2012 |
CERTIFICATE OF AMENDMENT SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION LIPOSCIENCE, INC. Exhibit 3.1.1 Exhibit 3.1.1 CERTIFICATE OF AMENDMENT TO SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF LIPOSCIENCE, INC. LIPOSCIENCE, INC., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify as of this [ ] day of [ ], 2012: FIRST: The name of the Corporation is LIPOSCIENCE, INC. SECO |
|
| April 27, 2012 |
Exhibit 10.8.1 Exhibit 10.8.1 LEASE AMENDMENT NO. 3 THIS LEASE AMENDMENT NO. 3 (this “Amendment”) is made this 29th day of November, 2011 (“Execution Date”), by and between Raleigh Portfolio JH, LLC (“Landlord”) and LipoScience, Inc. (formerly known as LipoMed, Inc.) (“Tenant”). WHEREAS, Parker-Raleigh Development XXX, LLC (“PRD”) and Tenant entered into a written agreement of Lease executed Octob |
|
| April 27, 2012 |
COLLABORATION AGREEMENT BY AND BETWEEN LIPOSCIENCE, INC. VARIAN, INC. DATED AS OF APRIL 22, 2005 Exhibit 10.9 Exhibit 10.9 *** Text Omitted and Filed Separately Confidential Treatment Requested Under 17 CFR §§ 200.80(b)(4) and 230.406 COLLABORATION AGREEMENT BY AND BETWEEN LIPOSCIENCE, INC. AND VARIAN, INC. DATED AS OF APRIL 22, 2005 *** Text Omitted and Filed Separately Confidential Treatment Requested Under 17 CFR §§ 200.80(b)(4) and 230.406 COLLABORATION AGREEMENT THIS COLLABORATION AGREEM |
|
| April 27, 2012 |
FIFTH AMENDMENT LOAN AND SECURITY AGREEMENT Exhibit 10.1.1 Exhibit 10.1.1 FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENT This Fifth Amendment to Loan and Security Agreement is entered into as of March 29, 2012 (the “Amendment”) by and between SQUARE 1 BANK (“Bank”) and LIPOSCIENCE, INC. (“Borrower”). RECITALS Borrower and Bank are parties to that certain Loan and Security Agreement dated as of February 7, 2008, as may be amended from time t |
|
| April 27, 2012 |
Exhibit 10.10 Exhibit 10.10 *** Text Omitted and Filed Separately Confidential Treatment Requested Under 17 CFR §§ 200.80(b)(4) and 230.406 PRODUCTION AGREEMENT THIS PRODUCTION AGREEMENT (the “Agreement”), effective as of June 26, 2009 (the “Effective Date”), by and between LIPOSCIENCE, INC., a Delaware corporation, (“LipoScience”) and KMC SYSTEMS, INC., a Delaware corporation (“KMC”). Capitalized |
|
| April 27, 2012 |
Correspondence Brent B. Siler (703) 456-8058 [email protected] VIA EDGAR April 27, 2012 U. S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 3561 Washington, D.C. 20549 Attn: Mr. John Reynolds Mr. Jay Williamson Mr. Jim Lopez Mr. Steve Lo Mr. John Archfield RE: LipoScience, Inc. Amendment No. 4 to Registration Statement on Form S-1 Registration No. |
|
| April 27, 2012 |
Amendment #4 Table of Contents As filed with the Securities and Exchange Commission on April 27, 2012 Registration No. |
|
| September 30, 2011 |
SEC Response Letter Brent B. Siler VIA EDGAR AND HAND DELIVERY (703) 456-8058 [email protected] September 30, 2011 U. S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 3561 Washington, D.C. 20549 Attn: Mr. John Reynolds Mr. Jay Williamson Mr. Jim Lopez Mr. Steve Lo Mr. John Archfield RE: LipoScience, Inc. Amendment No. 3 to Registration Statement on |
|
| September 30, 2011 |
Exhibit 10.10 Exhibit 10.10 *** Text Omitted and Filed Separately Confidential Treatment Requested Under 17 CFR §§ 200.80(b)(4) and 230.406 PRODUCTION AGREEMENT THIS PRODUCTION AGREEMENT (the “Agreement”), effective as of June 26, 2009 (the “Effective Date”), by and between LIPOSCIENCE, INC., a Delaware corporation, (“LipoScience”) and KMC SYSTEMS, INC., a Delaware corporation (“KMC”). Capitalized |
|
| September 30, 2011 |
[SIGNATURES ON FOLLOWING PAGE] Exhibit 10.35 Exhibit 10.35 *** Text Omitted and Filed Separately Confidential Treatment Requested Under 17 CFR §§ 200.80(b)(4) and 230.406 AGREEMENT This Agreement (“Agreement”) is entered into by and between Laboratory Corporation of America Holdings, a Delaware corporation having a place of business at 430 South Spring Street, Burlington, North Carolina 27215 (“LabCorp”), and LipoScience, Inc., |
|
| September 30, 2011 |
Amendment No. 3 to Form S-1 Table of Contents As filed with the Securities and Exchange Commission on September 30, 2011 Registration No. 333-175102 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 3 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 LIPOSCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 8071 56-18792 |
|
| September 30, 2011 |
COLLABORATION AGREEMENT BY AND BETWEEN LIPOSCIENCE, INC. VARIAN, INC. DATED AS OF APRIL 22, 2005 Exhibit 10.9 Exhibit 10.9 *** Text Omitted and Filed Separately Confidential Treatment Requested Under 17 CFR §§ 200.80(b)(4) and 230.406 COLLABORATION AGREEMENT BY AND BETWEEN LIPOSCIENCE, INC. AND VARIAN, INC. DATED AS OF APRIL 22, 2005 *** Text Omitted and Filed Separately Confidential Treatment Requested Under 17 CFR §§ 200.80(b)(4) and 230.406 COLLABORATION AGREEMENT THIS COLLABORATION AGREEM |
|
| August 19, 2011 |
Amendment #2 to Form S-1 Table of Contents As filed with the Securities and Exchange Commission on August 19, 2011 Registration No. |
|
| August 19, 2011 |
SEC Response Letter Brent B. Siler (703) 456-8058 [email protected] VIA EDGAR AND HAND DELIVERY August 19, 2011 U. S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 3561 Washington, D.C. 20549 Attn: Mr. John Reynolds Mr. Jay Williamson Mr. Jim Lopez Mr. Steve Lo Mr. John Archfield RE: LipoScience, Inc. Amendment No. 2 to Registration Statement on Fo |
|
| August 1, 2011 |
Correspondence Brent B. Siler (703) 456-8058 [email protected] VIA EDGAR AND HAND DELIVERY August 1, 2011 U. S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 3561 Washington, D.C. 20549 Attn: Mr. John Reynolds Mr. Jay Williamson Mr. Jim Lopez Mr. Steve Lo Mr. John Archfield RE: LipoScience, Inc. Registration Statement on Form S-1 Registration No. 3 |
|
| August 1, 2011 |
Exhibit 10.10 Exhibit 10.10 *** Text Omitted and Filed Separately Confidential Treatment Requested Under 17 CFR §§ 200.80(b)(4) and 230.406 PRODUCTION AGREEMENT THIS PRODUCTION AGREEMENT (the “Agreement”), effective as of June 26, 2009 (the “Effective Date”), by and between LIPOSCIENCE, INC., a Delaware corporation, (“LipoScience”) and KMC SYSTEMS, INC., a Delaware corporation (“KMC”). Capitalized |
|
| August 1, 2011 |
Exhibit 10.29 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of between LipoScience, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”). WITNESSETH THAT: WHEREAS, highly competent persons have become more reluctant to serve corporations as directors and/or officers or in other capacities unless they are provided with adequate pr |
|
| August 1, 2011 |
Exhibit 10.28 Exhibit 10.28 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of between LipoScience, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”). WITNESSETH THAT: WHEREAS, highly competent persons have become more reluctant to serve corporations as directors and/or officers or in other capacities unless they are provided wi |
|
| August 1, 2011 |
Table of Contents As filed with the Securities and Exchange Commission on August 1, 2011 Registration No. |
|
| August 1, 2011 |
NORTH CAROLINA UNIVERSITY LICENSE AGREEMENT Exhibit 10.11 Exhibit 10.11 *** Text Omitted and Filed Separately Confidential Treatment Requested Under 17 CFR § 200.80(b)(4) and 230.406 NORTH CAROLINA UNIVERSITY LICENSE AGREEMENT This Agreement is made by and between North Carolina State University (hereinafter referred to as “NCSU”), a constituent institution of the University of North Carolina and an educational institution organized under t |
|
| August 1, 2011 |
COLLABORATION AGREEMENT BY AND BETWEEN LIPOSCIENCE, INC. VARIAN, INC. DATED AS OF APRIL 22, 2005 Exhibit 10.9 Exhibit 10.9 *** Text Omitted and Filed Separately Confidential Treatment Requested Under 17 CFR §§ 200.80(b)(4) and 230.406 COLLABORATION AGREEMENT BY AND BETWEEN LIPOSCIENCE, INC. AND VARIAN, INC. DATED AS OF APRIL 22, 2005 *** Text Omitted and Filed Separately Confidential Treatment Requested Under 17 CFR §§ 200.80(b)(4) and 230.406 COLLABORATION AGREEMENT THIS COLLABORATION AGREEM |
|
| June 23, 2011 |
LIPOSCIENCE, INC. INCENTIVE STOCK OPTION AGREEMENT Exhibit 10.13 Exhibit 10.13 THE SECURITY REPRESENTED BY THIS CERTIFICATE HAS BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISPOSITION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURIT |
|
| June 23, 2011 |
Exhibit 10.6 Exhibit 10.6 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS, AND MAY NOT BE SOLD, PLEDGED OR OTHERWISE TRANSFERRED EXCEPT IN ACCORDANCE WITH APPLICABLE LAW. SECOND WARRANT TO PURCHASE STOCK Corporation: LIPOSCIENCE, INC. Number of Shares: 13,793 Class of Stock: Series F Conve |
|
| June 23, 2011 |
LIPOSCIENCE, INC. NONQUALIFIED STOCK OPTION AGREEMENT Exhibit 10.15 Exhibit 10.15 THE SECURITY REPRESENTED BY THIS CERTIFICATE HAS BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISPOSITION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURIT |
|
| June 23, 2011 |
Exhibit 10.2 Exhibit 10.2 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, OR ANY STATE SECURITIES LAWS, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH LAWS RELATED THERETO OR AN OPINIO |
|
| June 23, 2011 |
WARRANT TO PURCHASE PREFERRED STOCK OF LIPOSCIENCE, INC. (Void after December 31, 2011) Exhibit 10.3 Exhibit 10.3 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE AND DISTRIBUTION THEREOF, AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR ANY STATE SECURITIES LAWS. SUCH SECURITIES MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION O |
|
| June 23, 2011 |
Exhibit 10.8 Exhibit 10.8 STANDARD LEASE Parker Business Center - Building 307 and 308 This Lease is made by and between the Landlord and Tenant named below. ARTICLE 1. - BASIC LEASE TERMS For purposes of this Lease, the following terms shall have the meanings set forth below: 1.1 Landlord. Parker-Raleigh Development XXX, LLC 1.2 Tenant. Lipomed, Inc., a Delaware corporation 1.3 Manager. Parker Li |
|
| June 23, 2011 |
Exhibit 10.4 Exhibit 10.4 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AND PURSUANT TO THE PROVISIONS OF ARTICLE 5 BELOW, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND APPLICABLE STATE SECURI |
|
| June 23, 2011 |
LIPOSCIENCE, INC. SUMMARY OF RESTRICTED STOCK PURCHASE 2007 STOCK INCENTIVE PLAN Exhibit 10.22 Exhibit 10.22 LIPOSCIENCE, INC. SUMMARY OF RESTRICTED STOCK PURCHASE 2007 STOCK INCENTIVE PLAN LipoScience, Inc., a Delaware corporation (the “Company”) hereby issues and sells to the undersigned (the “Participant”), and the Participant hereby purchases from the Company, shares (the “Shares”) of the common stock of the Company, par value $0.001 per share (the “Common Stock”), pursuan |
|
| June 23, 2011 |
LIPOSCIENCE, INC. NOTICE OF NONSTATUTORY STOCK OPTION 2007 STOCK INCENTIVE PLAN Exhibit 10.18 Exhibit 10.18 LIPOSCIENCE, INC. NOTICE OF NONSTATUTORY STOCK OPTION 2007 STOCK INCENTIVE PLAN LipoScience, Inc., a Delaware corporation (the “Company”) grants to the undersigned (the “Participant”) the following nonstatutory stock option to purchase shares (the “Shares”) of the common stock of the Company, par value $0.001 per share (the “Common Stock”) pursuant to the Company’s 2007 |
|
| June 23, 2011 |
LIPOSCIENCE, INC. NOTICE OF NONSTATUTORY STOCK OPTION 2007 STOCK INCENTIVE PLAN Exhibit 10.19 Exhibit 10.19 LIPOSCIENCE, INC. NOTICE OF NONSTATUTORY STOCK OPTION 2007 STOCK INCENTIVE PLAN LipoScience, Inc., a Delaware corporation (the “Company”) grants to the undersigned (the “Participant”) the following nonstatutory stock option to purchase shares (the “Shares”) of the common stock of the Company, par value $0.001 per share (the “Common Stock”) pursuant to the Company’s 2007 |
|
| June 23, 2011 |
Exhibit 10.27 Exhibit 10.27 LipoScience, Inc. 2008 Director Compensation Plan Effective June 16, 2008 Amended June 18, 2009; February 3, 2010; and May 24, 2011 Directors of LipoScience, Inc. (the “Company”) who are neither employees of the Company nor representatives of institutional investors in the Company (hereinafter “independent directors”) shall be entitled to receive the following compensat |
|
| June 23, 2011 |
Registration Statement - FORM S-1 Form S-1 Table of Contents As filed with the Securities and Exchange Commission on June 23, 2011 Registration No. |
|
| June 23, 2011 |
LIPOSCIENCE, INC. INCENTIVE STOCK OPTION AGREEMENT Exhibit 10.14 Exhibit 10.14 THE SECURITY REPRESENTED BY THIS CERTIFICATE HAS BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISPOSITION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURIT |
|
| June 23, 2011 |
LIPOSCIENCE, INC. 2007 STOCK INCENTIVE PLAN Exhibit 10.16 Exhibit 10.16 LIPOSCIENCE, INC. 2007 STOCK INCENTIVE PLAN 1. Purpose The purpose of this 2007 Stock Incentive Plan (the “Plan”) of LipoScience, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important contributions to the Company |
|
| June 23, 2011 |
LIPOMED, INC. STOCK OPTION PLAN Exhibit 10.12 Exhibit 10.12 LIPOMED, INC. STOCK OPTION PLAN 1. Purpose. The LipoMed, Inc. Stock Option Plan (the “Plan”) is established to create an additional incentive for key employees, directors and consultants or advisors of LipoMed, Inc. and any successor corporations thereto (collectively referred to as the “Company”), and any present or future parent and/or subsidiary corporations of such |
|
| June 23, 2011 |
LIPOSCIENCE, INC. NOTICE OF NONSTATUTORY STOCK OPTION 2007 STOCK INCENTIVE PLAN Exhibit 10.20 Exhibit 10.20 LIPOSCIENCE, INC. NOTICE OF NONSTATUTORY STOCK OPTION 2007 STOCK INCENTIVE PLAN LipoScience, Inc., a Delaware corporation (the “Company”) grants to the undersigned (the “Participant”) the following nonstatutory stock option to purchase shares (the “Shares”) of the common stock of the Company, par value $0.001 per share (the “Common Stock”) pursuant to the Company’s 2007 |
|
| June 23, 2011 |
LIPOSCIENCE, INC. LOAN AND SECURITY AGREEMENT Exhibit 10.1 Exhibit 10.1 LIPOSCIENCE, INC. LOAN AND SECURITY AGREEMENT This LOAN AND SECURITY AGREEMENT (the “Agreement”) is entered into as of February 7, 2008, by and between Square 1 Bank (“Bank”) and LIPOSCIENCE, INC. (“Borrower”). RECITALS Borrower wishes to obtain credit from time to time from Bank, and Bank desires to extend credit to Borrower. This Agreement sets forth the terms on which |
|
| June 23, 2011 |
LIPOSCIENCE, INC. NOTICE OF NONSTATUTORY STOCK OPTION 2007 STOCK INCENTIVE PLAN Exhibit 10.21 Exhibit 10.21 LIPOSCIENCE, INC. NOTICE OF NONSTATUTORY STOCK OPTION 2007 STOCK INCENTIVE PLAN LipoScience, Inc., a Delaware corporation (the “Company”) grants to the undersigned (the “Participant”) the following nonstatutory stock option to purchase shares (the “Shares”) of the common stock of the Company, par value $0.001 per share (the “Common Stock”) pursuant to the Company’s 2007 |
|
| June 23, 2011 |
LIPOSCIENCE, INC. SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT Exhibit 10.7 Exhibit 10.7 LIPOSCIENCE, INC. SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT This Second Amended and Restated Investor Rights Agreement (the “Agreement”) is entered into as of August 2, 2006, by and among LipoScience, Inc., a Delaware corporation (formerly known as LipoMed, Inc.) (the “Company”), the holders of the Company’s Series D Preferred Stock (the “Series D Stock”) and |
|
| June 23, 2011 |
Exhibit 3.1 Exhibit 3.1 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF LIPOSCIENCE, INC. Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware LIPOSCIENCE, INC. (the “Corporation”), a corporation duly organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify as follows: 1. The name of the |
|
| June 23, 2011 |
BYLAWS LIPOMED, INC. ARTICLE I Exhibit 3.4 EXHIBIT 3.4 BYLAWS OF LIPOMED, INC. ARTICLE I OFFICES 1. Principal Office. The principal office of the Corporation shall be located in Wake County, North Carolina or such other place as is designated by the Board of Directors. 2. Registered Office. The registered office of the Corporation required by law to be maintained in the State of Delaware may be, but need not be, identical with |
|
| June 23, 2011 |
LIPOSCIENCE, INC. NOTICE OF INCENTIVE STOCK OPTION 2007 STOCK INCENTIVE PLAN Exhibit 10.17 Exhibit 10.17 LIPOSCIENCE, INC. NOTICE OF INCENTIVE STOCK OPTION 2007 STOCK INCENTIVE PLAN LipoScience, Inc., a Delaware corporation (the “Company”) grants to the undersigned (the “Participant”) the following incentive stock option to purchase shares (the “Shares”) of the common stock of the Company, par value $0.001 per share (the “Common Stock”), pursuant to the Company’s 2007 Stoc |
|
| June 23, 2011 |
Brian F. Leaf (703) 456-8053 [email protected] VIA EDGAR June 23, 2011 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 RE: LipoScience, Inc. – Registration Statement on Form S-1 Ladies and Gentlemen: On behalf of LipoScience, Inc., a Delaware corporation (the “Company”), we hereby electronically transmit, pursuant to the Securities Act of 1933, as amended (the “Act”), a |
|
| June 23, 2011 |
Exhibit 10.5 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS, AND MAY NOT BE SOLD, PLEDGED OR OTHERWISE TRANSFERRED EXCEPT IN ACCORDANCE WITH APPLICABLE LAW. WARRANT TO PURCHASE STOCK Corporation: LIPOSCIENCE, INC. Number of Shares: 75,000 Class of Stock: Series F Convertible Preferred Ini |
